RU2234322C2 - Препарат с улучшенной переносимостью in vivo - Google Patents

Препарат с улучшенной переносимостью in vivo Download PDF

Info

Publication number
RU2234322C2
RU2234322C2 RU98109154/15A RU98109154A RU2234322C2 RU 2234322 C2 RU2234322 C2 RU 2234322C2 RU 98109154/15 A RU98109154/15 A RU 98109154/15A RU 98109154 A RU98109154 A RU 98109154A RU 2234322 C2 RU2234322 C2 RU 2234322C2
Authority
RU
Russia
Prior art keywords
compound
active substance
acid
formula
sugar
Prior art date
Application number
RU98109154/15A
Other languages
English (en)
Russian (ru)
Other versions
RU98109154A (ru
Inventor
Клаус БОССЛЕТ (US)
Клаус Босслет
Йорг ЧЕХ (DE)
Йорг ЧЕХ
Манфред ГЕРКЕН (DE)
Манфред ГЕРКЕН
Райнер ШТРАУБ (DE)
Райнер ШТРАУБ
Маттиас БЛУМРИХ (DE)
Маттиас БЛУМРИХ
Original Assignee
Хехст Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст Акциенгезелльшафт filed Critical Хехст Акциенгезелльшафт
Publication of RU98109154A publication Critical patent/RU98109154A/ru
Application granted granted Critical
Publication of RU2234322C2 publication Critical patent/RU2234322C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU98109154/15A 1997-05-15 1998-05-14 Препарат с улучшенной переносимостью in vivo RU2234322C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19720312.4 1997-05-15
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit

Publications (2)

Publication Number Publication Date
RU98109154A RU98109154A (ru) 2000-03-10
RU2234322C2 true RU2234322C2 (ru) 2004-08-20

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98109154/15A RU2234322C2 (ru) 1997-05-15 1998-05-14 Препарат с улучшенной переносимостью in vivo

Country Status (17)

Country Link
US (1) US6020315A (enExample)
EP (1) EP0879605B1 (enExample)
JP (1) JP4367798B2 (enExample)
KR (1) KR100547923B1 (enExample)
CN (1) CN1188134C (enExample)
AR (1) AR012694A1 (enExample)
AT (1) ATE333899T1 (enExample)
AU (1) AU740694B2 (enExample)
BR (1) BR9801632A (enExample)
CA (1) CA2237450A1 (enExample)
CZ (1) CZ149398A3 (enExample)
DE (2) DE19720312A1 (enExample)
HU (1) HUP9801087A3 (enExample)
ID (1) ID20283A (enExample)
PL (1) PL193478B1 (enExample)
RU (1) RU2234322C2 (enExample)
TR (1) TR199800848A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0903348B2 (de) 1995-11-17 2008-08-27 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate und deren Herstellung
EP0941227B2 (de) 1996-11-18 2009-10-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
KR100685336B1 (ko) 1999-02-22 2007-02-23 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) Ｃ-21 변형 에포틸론
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
WO2000066612A1 (en) 1999-05-04 2000-11-09 Strakan Limited Androgen glycosides and androgenic activity thereof
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2004511510A (ja) * 2000-10-16 2004-04-15 ネオファーム、インコーポレイティッド ミトキサントロンのリポソーム製剤
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
JP2004522771A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー 治療抵抗性腫瘍の処置用エポチロン誘導体
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
EP1423126B1 (en) * 2001-08-14 2007-08-29 Valderm APS Treatment of hyperproliferative conditions of body surfaces
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
EP2114157B1 (en) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026454A1 (en) * 2011-08-22 2013-02-28 Valderm Aps Treatment of clinical conditions with anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511917A1 (fr) * 1991-04-30 1992-11-04 Laboratoires Hoechst S.A. Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
EP0751144A1 (en) * 1995-06-27 1997-01-02 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
SI0795334T1 (sl) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511917A1 (fr) * 1991-04-30 1992-11-04 Laboratoires Hoechst S.A. Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
EP0751144A1 (en) * 1995-06-27 1997-01-02 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Медицина, 1986, ч.2, с.457-464. *

Also Published As

Publication number Publication date
JP4367798B2 (ja) 2009-11-18
AU740694B2 (en) 2001-11-15
CA2237450A1 (en) 1998-11-15
TR199800848A3 (tr) 1998-12-21
CN1188134C (zh) 2005-02-09
EP0879605A2 (de) 1998-11-25
HUP9801087A3 (en) 1999-05-28
JPH1129497A (ja) 1999-02-02
HU9801087D0 (en) 1998-07-28
CZ149398A3 (cs) 1998-12-16
ID20283A (id) 1998-11-19
AU6600598A (en) 1998-11-19
DE59813653D1 (de) 2006-09-07
PL326336A1 (en) 1998-11-23
PL193478B1 (pl) 2007-02-28
DE19720312A1 (de) 1998-11-19
BR9801632A (pt) 1999-06-29
HUP9801087A2 (hu) 1998-12-28
EP0879605B1 (de) 2006-07-26
EP0879605A3 (de) 1998-12-02
AR012694A1 (es) 2000-11-08
KR19980087239A (ko) 1998-12-05
US6020315A (en) 2000-02-01
ATE333899T1 (de) 2006-08-15
CN1199613A (zh) 1998-11-25
KR100547923B1 (ko) 2006-04-12
TR199800848A2 (xx) 1998-12-21

Similar Documents

Publication Publication Date Title
RU2234322C2 (ru) Препарат с улучшенной переносимостью in vivo
RU98109154A (ru) Препарат с улучшенной переносимостью in vivo
US6146658A (en) Prodrugs, their preparation and use as pharmaceuticals
US5872104A (en) Combinations and methods for reducing antimicrobial resistance
EP0004467B1 (en) Bis-anthracyclines, methods of making and using them and liposome compositions for administering them
US7001888B2 (en) Compositions and methods for treating cancer
EP0795334B1 (de) Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
HUT52396A (en) Therapeutic combination compositions and their use as antineoplastics
US6420377B1 (en) Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US20130012466A1 (en) Colchicine neoglycosides and methods for their synthesis and use
UA45974C2 (uk) Терпеноїдні похідні (саркодиктиїни), що застосовуються як протипухлинні засоби
CN101402667A (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
DE69912099T2 (de) O6-benzylguanin-enthaltende oligodesoxyribonukleotide und deren verwendung
MXPA98003847A (en) Prepared with in vivo increment compatibility
US8552176B2 (en) Glycosylated chlorambucil analogs and uses thereof
RU2809635C1 (ru) Конъюгаты монометил ауристатина е с лигандами асиалогликопротеинового рецептора для направленного транспорта в опухолевые клетки печени
US20120108530A1 (en) Enhanced Neoglycosides Through Neoglycosylation and Methods of Use Thereof
WO2025177173A1 (en) Polymers useful for conjugating to antibodies and therapeutic uses thereof
Arcamone et al. Doxorubicin and related compounds. II. Structure-activity considerations
Montgomery Studies on the cytotoxic effects and mechanism of action of 1-phenyl-3-phenylamino-4-(p-toluenesulfinyl)-trans-1, 5-hexadiene
EP1754712A2 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
JPWO1997031928A1 (ja) 三糖性１−デオキシマンノジリマイシン誘導体

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070515